Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$1.07 USD
-0.01 (-0.93%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $1.07 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Oncolytics Biotech Inc. [ONCY]
Reports for Purchase
Showing records 41 - 60 ( 144 total )
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Milestones COVID-19 Proof, Cash Runway Into 2H21 - Reports 1Q20
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
ONCY and ORY.SM Disclose COVID-19 Related Delays
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Data from Several Clinical Trials Coming in 2020 - Reports 4Q19 Results
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
CEACAM6 is a Potential Prognostic Biomarker for Sensitivity to Pelareorep
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Discusses Likely Benefit of Proteasome Inhibition to Pelareorep
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
KOL Call - Proteasome Inhibitors Augment Pelareorep in Multiple Myeloma
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Viral Immunotherapy Targeting Several Oncology Indications - Data in 2Q20 -Transferring Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Oncolytics - Promising Oncolytic Virus for Multiple Tumors - Initiation of Coverage
Provider: Roth Capital Partners, Inc.
Analyst: ISAACSON J
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Lowering Price Target to $5; Q1:14 Financial Results and Update
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G